Browsing ICR Divisions by author "Chau, Ian"
Now showing items 1-20 of 27
-
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox, CP; Ali, AS; McIlroy, G; Thust, S; Martinez-Calle, N; et al.Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a ... -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei, M; Siemers, NO; Pandya, D; Chang, H; Sanchez, T; et al. (2021-03-29)Purpose In advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC), there is a need to identify biomarkers of response to therapies, such as immune checkpoint inhibitors.Patients and methods In post hoc exploratory ... -
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl, A; Cunningham, D; Chau, I (2017-09)After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery ... -
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez, E; Cubillo, A; Alfonso, PG; Middleton, MR; Chau, I; et al. (BMC, 2024-04-11)BACKGROUND: In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the ... -
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Fuchs, CS; Tabernero, J; Tomášek, J; Chau, I; Melichar, B; et al. (2016-10)Background Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell ... -
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; et al. (2018-10)Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and ... -
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau, I (2017-10)Gastrointestinal (GI) cancers are among the most deadly malignancies. Although serial incremental survival benefits have been made with cytotoxic chemotherapy with metastatic disease, a plateau of achievement has been ... -
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
Kitagawa, Y; Matsuda, S; Gotoda, T; Kato, K; Wijnhoven, B; et al. (SPRINGER, 2024-05-01) -
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Mendes, LST; et al. (2017-11)Background Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer.Methods mrTRG and pTRG were compared in rectal cancer patients from two phase ... -
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran, V; Xiao, H; Bertwistle, D; Zhang, Y; You, M; et al. (SPRINGER, 2020-11-26)INTRODUCTION: Management of locally advanced, unresectable, or metastatic (adv/met) esophageal adenocarcinoma (EAC) follows clinical guidance for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, ... -
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
Coyle, V; Forde, C; Adams, R; Agus, A; Barnes, R; et al. (NIHR JOURNALS LIBRARY, 2024-03-01)BACKGROUND: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. ... -
Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial.
Coyle, V; Forde, C; McAuley, DF; Wilson, RH; Clarke, M; et al. (ELSEVIER SCI LTD, 2023-07-28)OBJECTIVES: To determine whether early switch to oral antibiotic treatment in adults with neutropenic sepsis at low risk of complications is non-inferior to switching later. METHODS: This non-inferiority, parallel-group, ... -
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; et al. (2016-06)Background Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal ... -
Genomic loss of heterozygosity and survival in the REAL3 trial.
Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; et al. (2018-11-30)Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ... -
HER2 Inhibition in Gastric Cancer-Novel Therapeutic Approaches for an Established Target.
Fong, C; Chau, I (MDPI, 2022-08-06)Gastric cancer is a leading cause of cancer-related deaths globally. Human epidermal growth receptor 2 (HER2) overexpression of HER2 gene amplification is present in 20% of gastric cancers and defines a subset amenable to ... -
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Oh, D-Y; Maqueda, MA; Quinn, DI; O'Dwyer, PJ; Chau, I; et al. (BMC, 2023-11-03)BACKGROUND: Ibrutinib, a first-in-class inhibitor of Bruton's tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
Davidson, M; Chau, I; Cunningham, D; Khabra, K; Iveson, T; et al. (2017-08)Aim To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.Methods Individual patient data were pooled from three randomised phase III ... -
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.
Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; et al. (2017-09)This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ... -
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki, Y; Ajani, JA; Kato, K; Xu, J; Wyrwicz, L; et al.<h4>Background</h4>First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously ...